Syngene's capex on track; focus on R&D and biologics to fuel future expansion: Jonathan Hunt

​We predicted that during the course of this year, it would start to stabilise. We would see the beginnings recovery in that funding environment and that is exactly what has happened. A little bit later than I had expected it probably took a quarter, maybe half a quarter longer in the year for it to stabilise.